GeneDx Holdings (WGSWW) Change in Accured Expenses (2020 - 2026)

GeneDx Holdings has disclosed Change in Accured Expenses across 7 years of filings, most recently posting -$13.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 221.66% year-over-year to -$13.2 million; the TTM figure through Mar 2026 stood at -$11.9 million (down 139.42% YoY), while the FY2025 annual figure was $12.1 million, up 158.96% from the prior year.
• Change in Accured Expenses slipped to -$13.2 million in Q1 2026, from $6.9 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for WGSWW reached as high as $42.3 million in Q2 2022 and fell as low as -$14.5 million in Q3 2023.
• The 5-year median for Change in Accured Expenses is -$6.1 million (2024), against an average of -$2.1 million.
• The widest YoY moves for Change in Accured Expenses: up 459.2% in 2022, down 266.64% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at $5.9 million in 2022, then plunged by 256.79% to -$9.3 million in 2023, then plunged by 37.42% to -$12.7 million in 2024, then jumped by 154.38% to $6.9 million in 2025, then plunged by 290.43% to -$13.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$13.2 million, $6.9 million, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.